Biopharmaceutical Development Firm, BioFactura, Expands Frederick, Maryland, Facility
The company, which graduated last year from the Frederick Innovative Technology Center, recently built a 5,520 square-foot facility to accommodate its headquarters, as well as its research and development and manufacturing operations.
According to Maryland Department of Commerce, the expansion is expected to bring significant advancement to BioFactura’s development and manufacturing of generic biological drugs known as biosimilars. These products are highly similar alternatives to the very effective blockbuster drugs that are the major cost drivers for the increase in healthcare costs in the country.
“BioFactura’s biosimilars will allow for increased accessibility, reduction in price and improved outcomes for patients,” said Darryl Sampey, President/CEO of BioFactura. “We are excited with the expansion of our workforce, laboratories, and manufacturing in Frederick, and are grateful to the city and state for their support and investment.”
To assist with the expansion, the Maryland Department of Commerce has approved a $50,000 conditional loan through the Maryland Economic Development Assistance Authority and Fund (MEDAAF) program. The City of Frederick also approved a $10,000 conditional loan to help the company outfit its new facility.
“With world-class universities, key federal agencies like the U.S. Food and Drug Administration and the National Institutes of Health, and a critical mass of life sciences companies, Maryland offers an outstanding environment for emerging companies like BioFactura to grow and collaborate with industry partners,” said Maryland Commerce Secretary Mike Gill. “This new location will enable BioFactura to take their work with biosimilars to the next level of development and we are very excited to be a part of their success.”
? “We have been a big supporter of BioFactura since they were in the business incubator. We are delighted that they have decided to take space at the Riverside Research Park along with a number of other graduates,” said Richard Griffin, Director of Economic Development for the City of Frederick. “BioFactura represents the exact type of company we hope to assist so they can continue to create jobs and opportunities in Frederick.”
BioFactura develops and commercializes biodefense drugs, client-selected novel drugs, and high-value biosimilars. The company uses its patented StableFast™ Biomanufacturing platform system to bring these drugs to market faster, with lower cost and superior quality. Since 2004, BioFactura has been advancing life-saving medicines and has worked on drugs against smallpox and Ebola, new medicines for cancer, and biosimilars for autoimmune and infectious diseases.
In Focus: “Golden Age” of Spec Development
The 2021 Top States for Doing Business Reflect Their Locational Advantages
Area Development’s 17th Annual Shovel Awards Recognize State and Local Economic Development Efforts — First Two Platinum Shovels Awarded
In Focus: Demand for Industrial Land Surges
Explosive Growth of Life Sciences Sector Comes with Challenges
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
The Evolution of the Megasite